--- title: "CervoMed (CRVO) news: going concern, offering and lawsuit" url: "https://aibio.space/companies/cervomed/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CRVO going concern, offering and lawsuit news: CervoMed sets up at-the-market program for up to $50,000,000 with Leerink Partners. CervoMed Inc." --- CRVO CervoMed Inc. NASDAQ · United States # CervoMed (CRVO) news CRVO going concern, offering and lawsuit news Legal · 2026-08-07 ## [CervoMed discloses ex-CEO's 2014 suit, narrowed in March, with trial set for October](https://aibio.space/news/cervomed-discloses-ex-ceos-2014-suit-narrowed-march-trial-set-october/) Paul Feller sued RestorGenex, Pro Sports & Entertainment, ProElite and Stratus Media Group, GmbH in Los Angeles. The court dismissed some claims on March 26, 2026. CervoMed says it is defending itself vigorously. ## Latest CervoMed news 1. 2025-05-12 Financings [CervoMed sets up at-the-market program for up to $50,000,000 with Leerink Partners](https://aibio.space/news/cervomed-sets-up-market-program-up-50-000-000-leerink-partners/) Leerink Partners earns 3.0% of any gross proceeds, and CervoMed is not obliged to sell any shares. The prospectus supplement notes an auditor going-concern paragraph. ## CervoMed at a glance - **Ticker**: CRVO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $24.9 million ### Related companies - [Dyadic International](https://aibio.space/companies/dyadic-international/) NASDAQ: DYAI - [Serina Therapeutics](https://aibio.space/companies/serina-therapeutics/) AMEX: SER - [Tectonic Therapeutic](https://aibio.space/companies/tectonic-therapeutic/) NASDAQ: TECX - [Polaryx Therapeutics](https://aibio.space/companies/polaryx-therapeutics/) NASDAQ: PLYX - [Celularity](https://aibio.space/companies/celularity/) NASDAQ: CELU - [Citius Pharmaceuticals](https://aibio.space/companies/citius-pharmaceuticals/) NASDAQ: CTXR - [MiMedx Group](https://aibio.space/companies/mimedx/) NASDAQ: MDXG - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) AMEX: EDVA ### Also on NASDAQ - [COMPASS Pathways Plc](https://aibio.space/companies/compass-pathways/) CMPS - [iTonic Holdings](https://aibio.space/companies/itonic/) ITOC - [Alumis](https://aibio.space/companies/alumis/) ALMS - [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) CTMX - [Sutro Biopharma](https://aibio.space/companies/sutro-biopharma/) STRO - [VERACYTE, INC.](https://aibio.space/companies/veracyte/) VCYT ## CervoMed annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$4.0 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | [$9.7 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | | Research and development | [$21.8 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | [$18.8 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | | Net income (loss) | [-$27.0 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | [-$16.3 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | | Cash from operations | [-$23.4 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | [-$16.5 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | | Cash and equivalents | [$8.2 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926026592/) | [$9.0 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | | Short-term investments | [$12.6 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926026592/) | [$29.9 million](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $22.5 million, plus short-term investments of $2.5 million, $24.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CervoMed Has CervoMed issued a going-concern warning? Our latest story on this, dated May 12, 2025: "CervoMed sets up at-the-market program for up to $50,000,000 with Leerink Partners". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cervomed-sets-up-market-program-up-50-000-000-leerink-partners/). Has CervoMed raised money recently? Our latest story on this, dated May 12, 2025: "CervoMed sets up at-the-market program for up to $50,000,000 with Leerink Partners". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cervomed-sets-up-market-program-up-50-000-000-leerink-partners/). Is CervoMed involved in a lawsuit? Our latest story on this, dated Aug 7, 2026: "CervoMed discloses ex-CEO's 2014 suit, narrowed in March, with trial set for October". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cervomed-discloses-ex-ceos-2014-suit-narrowed-march-trial-set-october/). What is the ticker symbol of CervoMed? CervoMed Inc. trades under the ticker CRVO on NASDAQ. Where is CervoMed listed? CervoMed Inc. is listed on NASDAQ. What is the SEC CIK of CervoMed? The SEC Central Index Key (CIK) for CervoMed Inc. is 1053691. Its filings are on SEC EDGAR. How many shares does CervoMed have outstanding? 15,119,096 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is CervoMed listed under? Our directory records CervoMed Inc. under United States. What does CervoMed do? Our directory classifies CervoMed Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of CervoMed? The ISIN recorded for CervoMed Inc. is US15713L1098. Does aibio.space cover CervoMed? aibio.space lists CervoMed Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is CervoMed incorporated? SEC records list its state or country of incorporation as DE. What was CervoMed's revenue last year? $4.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is CervoMed profitable? CervoMed Inc. reported a net loss of $27.0 million for the fiscal year ended Dec 31, 2025, and used $23.4 million of cash in operations, per its annual report to the SEC. How much does CervoMed spend on research and development? $21.8 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: CervoMed Members talk about CervoMed (CRVO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at CervoMed, newest first. Each line links the filing it comes from. 1. 2026-06-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1053691/000143774926021208/crvo20260618_8k.htm) 2. 2026-06-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1053691/000143774926020080/crvo20260610_8k.htm) 3. 2025-11-07 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1053691/000143774925033879/crvo20250930_10q.htm) 4. 2025-05-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/crvo20250509_8k.htm) 5. 2025-04-18 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1053691/000143774925012337/crvo20250417_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CRVO on TradingView](https://www.tradingview.com/symbols/NASDAQ-CRVO/). ## SEC filings and registration - **SEC name**: CervoMed Inc. - **CIK**: 1053691 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CRVO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 20 PARK PLAZA, BOSTON, MA, 02116 - **Phone**: (617) 744-4400 - **Shares outstanding**: 15,119,096 as of 2026-08-06 (10-Q filed 2026-08-07) - **Former names**: Diffusion Pharmaceuticals Inc.; RestorGenex Corp; Stratus Media Group, Inc ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1053691/000143774926032620/crvo20261014_8k.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/crvo20261012_8k.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1053691/000143774926032445/crvo20261009_8k.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1053691/000143774926031389/crvo20260928_8k.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1053691/000143774926030073/crvo20260910_8k.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/crvo20260810_8k.htm) filed 2026-08-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1053691/000143774926026592/crvo20260630_10q.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1053691/000143774926025509/crvo20260803_8k.htm) filed 2026-08-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053691), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details CervoMed Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CRVO, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CervoMed Inc. - **Ticker**: CRVO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US15713L1098 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CRVO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cervomed/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CervoMed (CRVO) news: going concern, offering and lawsuit", 2026-10-31, https://aibio.space/companies/cervomed/